ОТ ПАТОЛОГИЧЕСКИХ ПРОЦЕССОВ К ПАТОГЕНЕЗУ ЛЕКАРСТВЕННОЙ АЛЛЕРГИИ

Обложка

Цитировать

Полный текст

Аннотация

В современной медицине огромный интерес вызывает анализ природы аллергиче- ских заболеваний с позиций целостного организма. В настоящей статье приводятся суммарный подход к оценке патогенеза аллергического заболевания, который дает возможность понять ряд ситуаций, которые можно наблюдать в области практической аллергологии. Известно, что сен- сибилизация организма может проявляться к различного рода факторам (аллергенам), как до- статочно экзотическим по своим свойствам, так и не обладающим никакими специфическими характеристиками, то есть симптомы аллергического состояния могут проявиться и вне зави- симости от вида аллергена. Любое аллергическое состояние нужно рассматривать через призму реакции всего организма, уровень которой является отражением его реактивности. Вот почему симптомы аллергии необходимо рассматривать как дополнительные защитные механизмы, ко- торые включаются в регуляцию гомеостаза при определенной, часто не проявляющейся клини- чески несостоятельности дренажно-дезинтоксикационных функций организма.

Об авторах

И Р Мавлянов

Ташкентская медицинская академия

А Х Аширметов

Ташкентская медицинская академия

З И Мавлянов

Ташкентская медицинская академия

Список литературы

  1. Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral betalactam antibiotics in patients with cystic fibrosis. Chest 1994; 106: 11241128.
  2. Pavlos R, Phillips EJ. Individualization of antiretroviral therapy. Pharmgenomics Pers Med. 2012; 5: 117.
  3. Pichler WJ. Drug Hypersensitivity. Karger, Basel; 2007.
  4. Adam J., Pichler W.J., Yerly D. Delayed drug hypersensitivity: models of Tcell stimulation Br J ClinPharmacol. 2010; 71:5 / 701707.
  5. Аsensi V., Collazos J., ValleGaray E. Can antiretroviral therapy be tailored to each human immunodeficiency virusinfected individual? Role of pharmacogenomics World J Virol. 2015; 12, № 4 (3): 169177.
  6. Wah Fung Tse, Weimin Yang, Wenlong Huang. A narrative review of costeffectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes Clinicoecon Outcomes Res. 2015; 7: 431439.
  7. Новиков Д.К., Сергеев Ю.В., Новиков П.Д. Лекарственная аллергия, М. 2001, 312 с.
  8. ElGhaiesh S, Monshi MM, Whitaker P, et al. Characterization of the antigen specificity of Tcell clones from piperacillinhypersensitive patients with cystic fibrosis. J Pharmacol ExpTher 2012; 341: 597610.
  9. Castrejon JL, Berry N, ElGhaiesh S, et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy ClinImmunol 2010; 125: 4118.e4.
  10. Watkins S, Pichler WJ. Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVbeta201, altering pHLA recognition. PLoS One 2013; 8: e76211.
  11. Wuillemin N, Adam J, Fontana S, et al. HLA haplotype determines hapten or pi T cell reactivity to flucloxacillin. J Immunol 2013; 190: 495664.
  12. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)B*57:01restricted activation of drugspecific T cells provides the immunological basis for flucloxacillininduced liver injury. Hepatology 2013; 57: 72739.
  13. Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. SciTransl Med 2010; 2: 4662.
  14. Mallal S, Nolan D, Witt C, et al. Association between presence of HLAB*5701, HLADR7, and HLADQ3 and hypersensitivity to HIV1 reversetranscriptase inhibitor abacavir. Lancet 2002; 359: 727732.
  15. McCormack M, Alfirevic A, Bourgeois S, et al. HLAA*3101 and carbamazepineinduced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 11341143.
  16. Hung SI, Chung WH, Liou LB, et al. HLAB*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. ProcNatlAcadSci USA 2005; 102: 41344139.
  17. Cargnin S, Jommi C, Canonico PL, et al. Diagnostic accuracy of HLAB*57: 01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a metaanalytic review. Pharmacogenomics. 2014; 15: 963976.
  18. Pirmohamed M, Back DJ. The pharmacogenomics of HIV therapy. Pharmacogenomics J. 2001; 1: 243253.
  19. Vitezica ZG, Milpied B, Lonjou C, et al. HLADRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22: 540541.
  20. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapineassociated cutaneous and hepatic adverse events among populations of African,Asian, and European descent. AIDS 2011; 25: 12711280.
  21. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLAB*3505 alleleis a strong predictor for nevirapineinduced skin adverse drug reactions inHIVinfected Thai patients. Pharmacogenet Genomics 2009; 19: 139146.
  22. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapineassociated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006; 43: 783786.
  23. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLADRB1*0101 and abrogated by low CD4 Tcell counts. AIDS. 2005; 19: 9799.
  24. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLAB*1502 and carbamazepineinduced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010; 51: 92630.
  25. Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2010; 49: 83441.
  26. Lonjou C, Borot N, Sekula P, et al. A European study of HLAB in StevensJohnson syndrome and toxic epidermal necrolysis related to five highrisk drugs. Pharmacogenet Genomics 2008; 18: 99107.
  27. Ikeda H, Takahashi Y, Yamazaki E, et al. HLA class I markers in Japanese patients with carbamazepineinduced cutaneous adverse reactions. Epilepsia 2010; 51: 297300.
  28. Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, et. al. HLAA* 31:01 and different types of carbamazepineinduced severe cutaneous adverse reactions: an international study and metaanalysis. Pharmacogenomics J 2014; 14: 281288.
  29. McCormack M, Alfirevic A, Bourgeois S, et. al. HLAA*3101 and carbamazepineinduced hypersensitivity reactionsin Europeans. N Engl J Med 2011; 364: 11341143.
  30. Ozeki T, Mushiroda T, Yowang A, et al. Genomewide association study identifies HLAA*3101 allele as a genetic risk factor for carbamazepineinduced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20: 10341041.
  31. Lichtenfels M, Farrell J, Ogese MO, et al. HLA restriction of carbamazepinespecific TCell clones from an HLAA*31:01positive hypersensitive patient. Chem Res Toxicol 2014; 27: 175177.
  32. Rodriguesa R. de Oliveira, Germano P. de Carvalhoa, Gomes E.A. de Arrudac et al. Interleukin10 gene polymorphism (-1082G/A) and allergy to efavirenz in patients infected with human immunodeficiency virus Braz J infect dis. 2014; 18 (4): 445448.
  33. Jinno H, TanakaKagawa T, OhnoA et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug MetabDispos 2003; 31: 398403.
  34. Yuan J, Guo S, Hall D et al. Toxicogenomics of nevirapineassociatedcutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25: 12711280.
  35. Sinxadi PZ, Leger PD, McIlleron HM, et al. Pharmacogenetics of plasma efavirenz exposure in HIVinfected adults and children in South Africa. Br J ClinPharmacol. 2015; 80: 146156.
  36. Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoinrelated severe cutaneous adverse reactions. JAMA 2014; 312: 52534.
  37. Thornhill J., Fidler S., Frater J. Advancing the HIV cure agenda: the next 5 years. Current Opinion in Infectious Diseases. 2015; 28 (1): 19.
  38. Di Santo R. Inhibiting the HIV integration process: past, present, and the future. J Med Chem. 2014; 57: 539566.
  39. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1*11:01 in antihydroxymethylglutaryl coenzyme A reductaseassociated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012; 64: 12331237.
  40. Goldstein JI, Jarskog LF, Hilliard C, et al. Clozapineinduced agranulocytosis is associated with rare HLADQB1 and HLAB alleles. Nat Commun 2014; 5: 4757.
  41. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepineinduced cutaneous adverse drug reactions: a systematic review. ClinPharmacolTher 2012; 92: 757565.
  42. Lonjou C, Thomas L, Borot N, et al. A marker for StevensJohnson syndrome.: ethnicity matters. Pharmacogenomics J 2006; 6: 265268.
  43. Mallal S, Phillips E, Carosi G, et al. HLAB*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568579.
  44. Daly AK, Donaldson PT, Bhatnagar P, et al. HLAB*5701 genotype is a major determinant of druginduced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816819.
  45. Singer JB, Lewitzky S, Leroy E, et al. A genome wide study identifies HLA alleles associated with lumiracoxibrelated liver injury. Nat Genet 2010; 42: 711714.
  46. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillinclavulanateinduced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338347.
  47. Hebbring SJ, Schrodi SJ, Ye Z, et al. A PheWASapproach in studying HLADRB1*1501. Genes Immun 2013; 14: 187191.
  48. Pirmohamed M, Park K. Mechanism of clozapineinduced agranulocytosis: current status of research and implications for drug development. CNS Drugs 1997; 7: 139158.
  49. Clay PG. The abacavir hypersensitivity reaction: a review. ClinTher 2002; 24: 15021514.
  50. Gueant JL, Romano A, CornejoGarcia JA, et al. HLADRA variants predict penicillin allergy in genomewide fine mapping genotyping. J Allergy ClinImmunol 2015; 135: 253259.

© Мавлянов И.Р., Аширметов А.Х., Мавлянов З.И., 2017

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах